US 11,780,930 B2
CD38 modulating antibody
Pascal Merchiers, Stevenage (GB); Anne Goubier, Stevenage (GB); Kevin Moulder, Stevenage (GB); Nina Eissler, Stevenage (GB); Josephine Salimu, Stevenage (GB); Simone Filosto, Stevenage (GB); Beatriz Goyenechea Corzo, Stevenage (GB); Hemanta Baruah, Lebanon, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to BLACK BELT THERAPEUTICS LIMITED, Stevenage (GB)
Appl. No. 16/620,584
Filed by BLACK BELT THERAPEUTICS LIMITED, Stevenage (GB)
PCT Filed Jun. 8, 2018, PCT No. PCT/EP2018/065237
§ 371(c)(1), (2) Date Dec. 9, 2019,
PCT Pub. No. WO2018/224682, PCT Pub. Date Dec. 13, 2018.
Claims priority of provisional application 62/582,681, filed on Nov. 7, 2017.
Claims priority of provisional application 62/582,653, filed on Nov. 7, 2017.
Claims priority of provisional application 62/582,628, filed on Nov. 7, 2017.
Claims priority of provisional application 62/582,616, filed on Nov. 7, 2017.
Claims priority of provisional application 62/582,666, filed on Nov. 7, 2017.
Claims priority of provisional application 62/582,676, filed on Nov. 7, 2017.
Claims priority of provisional application 62/546,330, filed on Aug. 16, 2017.
Claims priority of provisional application 62/546,322, filed on Aug. 16, 2017.
Claims priority of provisional application 62/517,740, filed on Jun. 9, 2017.
Claims priority of provisional application 62/517,745, filed on Jun. 9, 2017.
Claims priority of provisional application 62/517,165, filed on Jun. 9, 2017.
Claims priority of provisional application 62/517,164, filed on Jun. 9, 2017.
Claims priority of provisional application 62/517,753, filed on Jun. 9, 2017.
Claims priority of provisional application 62/517,734, filed on Jun. 9, 2017.
Claims priority of provisional application 62/517,149, filed on Jun. 8, 2017.
Claims priority of provisional application 62/517,150, filed on Jun. 8, 2017.
Prior Publication US 2020/0190209 A1, Jun. 18, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. An anti-CD38 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:
a) the amino acid sequence of SEQ ID NO: 11 as variable heavy chain complementarity determining region 3;
b) amino acid sequence of SEQ ID NO: 9 as variable heavy chain complementarity determining region 1;
c) amino acid sequence of SEQ ID NO: 10 as variable heavy chain complementarity determining region 2;
d) amino acid sequence of SEQ ID NO: 13 as variable light chain complementarity determining region 1;
e) amino acid sequence of SEQ ID NO: 14 as variable light chain complementarity determining region 2; and
f) amino acid sequence of SEQ ID NO: 15 as variable light chain complementarity determining region 3.